Latest Articles
Pembrolizumab Plus Chemotherapy Shows Sustained Survival in Advanced EC - CancerNetwork
Pembrolizumab Plus Chemotherapy Shows Sustained Survival in Advanced EC CancerNetwork
Published: May 30, 2026, 12:40 a.m.
Immunotherapy Addition Demonstrates Sustained Survival Benefits in - Bioengineer.org
Immunotherapy Addition Demonstrates Sustained Survival Benefits in Bioengineer.org
Published: May 29, 2026, 11:56 p.m.
Gilberto Lopes: New Study Suggests Survival Benefit With GLP-1 RAs in Endometrial Cancer - Oncodaily
Gilberto Lopes: New Study Suggests Survival Benefit With GLP-1 RAs in Endometrial Cancer Oncodaily
Published: May 25, 2026, 7:06 p.m.
Antibody-Drug Conjugate Improves Survival for Endometrial Cancer Patients - Labroots
Antibody-Drug Conjugate Improves Survival for Endometrial Cancer Patients Labroots
Published: May 25, 2026, 10 a.m.
New therapy bests chemo to improve survival in endometrial cancer - Rare Cancer News
New therapy bests chemo to improve survival in endometrial cancer Rare Cancer News
Published: May 20, 2026, 1:14 p.m.
Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer - BioSpace
Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer BioSpace
Published: May 19, 2026, 11:19 a.m.
Merck-Kelun ADC boosts survival in phase 3 endometrial cancer, stokes TROP2 race - CHOSUNBIZ - Chosunbiz
Merck-Kelun ADC boosts survival in phase 3 endometrial cancer, stokes TROP2 race - CHOSUNBIZ Chosunbiz
Published: May 19, 2026, 6:54 a.m.
Sacituzumab Tirumotecan Improves Survival in Advanced Endometrial Cancer - Targeted Oncology
Sacituzumab Tirumotecan Improves Survival in Advanced Endometrial Cancer Targeted Oncology
Published: May 18, 2026, 1:33 p.m.
Merck endometrial cancer drug meets survival goals in phase 3 trial - StreetInsider
Merck endometrial cancer drug meets survival goals in phase 3 trial StreetInsider
Published: May 18, 2026, 10:47 a.m.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire
Published: May 18, 2026, 10:45 a.m.
Link copied to clipboard!